Samtasu Post-marketing General Drug Use-results Survey in Patients with Volume Overload in Heart Failure.

NCT05712746 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1600

Last updated 2025-03-21

No results posted yet for this study

Summary

To confirm the safety of tolvaptan sodium phosphate in patients with volume overload in heart failure.

Conditions

Interventions

DRUG

Samtasu for I.V. infusion

Drug: 8 mg/vial or 16mg/vial Dosage and Administration: The usual adult dosage of tolvaptan sodium phosphate is 16 mg once daily and intravenously infused over 1 hour.

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yasuhiko Fukuta, PhD · Otsuka Pharmaceutical Co., Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-03
Primary Completion
2025-11-30
Completion
2026-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05712746 on ClinicalTrials.gov